Progress with inactivated poliovirus vaccines derived from the Sabin strains.
To produce a safe and effective inactivated poliovirus vaccine (IPV), we have developed S-IPV using Vero cells infected with the Sabin strains in a semi-production scale. All production steps including virus culture on microcarrier beads were highly reproducible. Mean recovery percents of infectious viruses or D-antigens during all processes for concentration, purification and inactivation were 30-50% in the three types. The S-IPV potency was adjusted for D-antigen content as determined by in-house ELISA and was comparable to WHO reference IPV derived from the virulent strains in immunogenicity tests in rats. Antibody development in more than 30 seronegative infant volunteers after two shots of S-IPV at four-week interval were 100% without notable adverse reactions. The mean antibody titres (log2) to Sabin 1, 2 and 3 viruses were 11.1, 8.3 and 8.9, respectively. The antibodies neutralized the Mahoney, MEF-1, and Saukett virulent strains with slightly inferior titres to those of the Sabin strains. D-antigens for each type of S-IPV were stable at 4 degrees C without any significant decrease over more than two years.
Doi
Y
Y
Japan Poliomyelitis Research Institute, Tokyo.
Abe
S
S
Yamamoto
H
H
Horie
H
H
Ohyama
H
H
Satoh
K
K
Tano
Y
Y
Ota
Y
Y
Miyazawa
M
M
Wakabayashi
K
K
Hashizume
S
S
D000328:Adult; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000276:immunology; D002522:Chlorocebus aethiops; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008297:Male; D009500:Neutralization Tests; D011051:Poliomyelitis / Q000276:immunology / Q000517:prevention & control*; D017955:Poliovirus / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity / Q000502:physiology; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage / Q000276:immunology*; D051381:Rats; D017208:Rats, Wistar; D014709:Vero Cells
D000914:Antibodies, Viral; D011054:Poliovirus Vaccine, Inactivated